Ita New

Indications

• Ventricular tachycardia
• Atrial fibrillation
• Atrial flutter
• Supraventricular tachycardia

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated.

Mechanism of action

Sotalol acts by blocking beta-adrenergic receptors, which leads to a decrease in heart rate and myocardial contractility. Additionally, it prolongs the cardiac action potential and refractory period through potassium channel blockade, which helps in stabilizing the cardiac rhythm.

Pharmacodynamics

The pharmacodynamics of sotalol involve its dual action as a beta-adrenergic blocker and a potassium channel blocker. This results in decreased conduction velocity in the heart, particularly in the atria and ventricles, which is beneficial in treating arrhythmias. The drug's effects on heart rate and contractility are dose-dependent, and the antiarrhythmic effects may take several hours to manifest after administration.

Pharmacokinetics

Sotalol is well absorbed from the gastrointestinal tract, with approximately 90% bioavailability. It has a long elimination half-life of around 12 hours, allowing for twice-daily dosing. The drug is primarily excreted unchanged in the urine, necessitating dose adjustment in patients with renal impairment. It does not undergo significant hepatic metabolism.

Interactions

• propafenone+sotalol: Unknown (increases risk of cardiovascular adverse effects)
• chloroprocaine+sotalol: Unknown (increases risk of cardiovascular adverse effects)

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.